K+S

We enrich life for generations

The products and services of K+S are crucial for supplying the population in the fields of medicine, pharmaceuticals, food production, agriculture and animal feed. By using our underground caverns, we also contribute to an orderly waste management system.

Ad hoc disclosure of October 26, 2021

Forecast K+S Aktiengesellschaft

K+S raises operating EBITDA outlook for 2021 again to around EUR 630 million (previously: EUR 500 to 600 million; excluding REKS transaction)
Balanced free cash flow expected for 2021 (previously: EUR -180 million; excluding REKS transaction)
Antitrust review of REKS transaction still ongoing

To the ad hoc disclosure

Half-Year Financial Report H1/2021

Get informed about the half-year financial report as well as quarterly reports and additional information from the financial year 2021.

Strong second quarter in 2021

EBITDA doubled - 2021 forecast raised

K+S announced the final figures for the second quarter of 2021. As already announced, the EBITDA more than doubled and the EBITDA forecast for 2021 was raised once again.

To the press release

Half-Year Financial Report 2021

Positive outlook for the rest of the year

In an interview, Dr. Burkhard Lohr, CEO of K+S AG, explains the business development of the company in the second quarter of 2021 and provides an oulook for the current year.

Press release of June 29, 2021

K+S reduces financial liabilities by €560 million through successful buy-back of bonds

Read our latest publications about "K+S reduces financial liabilities by €560 million through successful buy-back of bonds".

To the press release

Annual Report 2020

Read all numbers and facts about K+S in our new 2020 Annual Report.

Difficult conditions: The declined EBITDA from continuing and discontinued operations in 2020 (2019: €640 million) was mainly attributable to lower potash prices, a weaker de-icing salt business due to weather conditions, corona, and one-off expenses associated with the restructuring of the administrative functions.

Get more details

K+S pharmaceutical salt (APISAL®) is produced by a highly developed evaporated salt process and contains no additives.

Transportation medium for the corona vaccine

The Biontech/Pfizer corona vaccine COMIRNATY® is only applicable with the addition of high-purity sodium chloride solution. K+S is one of the largest manufacturers of the pharmaceutical-grade sodium chloride required for this purpose.

To the press release

Dealing with the corona pandemic

It is part of our social responsibility to serve the needs of our customers in the medical, pharmaceutical, food production, animal feed and agricultural sectors in the best possible way and to ensure the safe disposal of waste.

Digitalization in Africa’s agriculture

Together with local partners, K+S offers the EzyAgric App in Africa, which helps small-scale farmers to improve their harvests thereby raising their standard of living.

Focus on four business segments

K+S's business is focused on four segments: agriculture, industry, consumers, and communities. The same applies in all segments: The customer is the focus of our activities.

K+S - With it's roots in the region, at home all over the world

With roots in the region, at home all over the world. K+S has production sites in Europe and North America, as well as further distribution sites in Africa and Asia.

1 company, 1,000 possibilities: The wide range of career opportunities at K+S

More than 11,000 employees work for us at 50 sites worldwide. Here you will find detailed information about national and international entry and career opportunities.

We care

We strive for sustainability, because we acknowledge our responsibility to the people, the environment, the communities, and the economy in the regions in which we operate.